160 results on '"Resteghini C"'
Search Results
2. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer
3. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients
4. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact
5. Low etiologic fraction for human papillomavirus in larynx squamous cell carcinoma
6. 232MO Transcriptomic and tumor microenvironment landscape of EBV related nasopharyngeal carcinoma in endemic and non-endemic areas
7. 224O Survival differences between EU and Asia for head and neck cancer: Results of the RARECAREnet-Asia collaboration
8. 708TiP BD4QoL: A multicenter randomized trial for monitoring quality of life (QoL) by intelligent tools in head and neck cancer (HNC) survivors after curative treatment
9. 664P A multicentre retrospective analysis of recurrent/metastatic (RM) nasopharyngeal cancer (NPC) from non-endemic areas: Results in the pre-immunotherapy era
10. 891P Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer: The POINT study
11. 856P Safety of neoadjuvant PARP inhibitor and immunotherapy in locally advanced HPV-negative head and neck squamous cell carcinoma (PRIME H&N Study)
12. Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding
13. A multicentre retrospective analysis of recurrent/metastatic (RM) nasopharyngeal cancer (NPC) from non-endemic areas: Results in the pre-immunotherapy era
14. 868P A phase II trial of induction chemotherapy (IC), photon-, proton- and carbon ion-based radiotherapy (RT) integration in locally advanced inoperable sinonasal epithelial tumors patients (pts)
15. 2221P Precision oncology in advanced thyroid carcinomas: Impact of molecular tests on patients’ outcomes
16. PH-0043: Age related toxicity and outcome in oropharyngeal and nasoparyngeal cancer patients
17. PO-165 Phase 2 study on axitinib in recurrent/metastatic salivary gland cancer of upper aerodigestive tract
18. PO-115 Radiomics-based prediction of response to induction chemotherapy in sinonasal cancer
19. PO-161 Mutational profile of epithelial, non-glandular sinonasal cancers into 2 prospective clinical trials
20. Big Data in Head and Neck Cancer
21. 1065P A retrospective multicenter Italian analysis of the effect of longer vismodegib intake in 68 basal cell carcinoma patients who achieved clinical complete remission
22. Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy
23. Prognostic Value of Metabolic Parameters by 18 F-FDG PET/CT in Nasopharyngeal Cancer (NPC) in Non-Endemic Area
24. Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma
25. A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma
26. Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer
27. A single institution twenty-year experience of recurrent or metastatic epithelial non glandular sinonasal cancer
28. Sinonasal non-glandular cancers relapsing after multimodal treatments
29. RetroSpective cohort stUdy of PD-L1 expression in REcurrent and/or MEtastatic squamous cell carcinoma of the head and neck (SUPREME-HN)
30. PD-034: Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer
31. Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): A retrospective analysis
32. Upregulation of RAS pathway to predict the risk of distant metastases in HPV plus oropharynx cancer
33. Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting
34. Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer: a single center experience
35. Retreatment with Vismodegib is active in progressive advanced Basal Cell Carcinoma: first report from a single-Institution experience
36. An added value to Multidisciplinary Team: does a Tutor help to manage head and neck cancer patients?
37. Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients
38. RANK expression in EBV associated nasopharyngeal cancer metastasis in non-endemic setting: a possible immunologic pathway to be targeted?
39. Prognostic role of PI3KCA and TP53 in HPV-negative oropharyngeal cancers (OPCs)
40. Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area
41. Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer
42. Site of metastatic disease influences adenoid cystic cancer (ACC) patients' outcome
43. Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): a retrospective analysis
44. 2865 Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): A retrospective analysis
45. 2827 Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer
46. L2 - Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma
47. L6 - Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer
48. L5 - A single institution twenty-year experience of recurrent or metastatic epithelial non glandular sinonasal cancer
49. G1 - A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma
50. Prognostic Value of Metabolic Parameters by 18F-FDG PET/CT in Nasopharyngeal Cancer (NPC) in Non-Endemic Area
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.